Arbutus Biopharma (ABUS) Wins FDA Fast Track for Imdusiran

Arbutus Biopharma Corporation (NASDAQ:ABUS) is one of the 10 Best Penny Stocks to Buy and Hold Under $5. On April 14, 2026, ...
InvestorsHub on MSN

Arbutus shares jump after FDA grants fast track status to hepatitis B therapy

Arbutus Biopharma Corporation (NASDAQ:ABUS) shares climbed 6% on Wednesday after the company revealed it had received Fast ...

Arbutus Receives U.S. FDA Fast Track Designation for Imdusiran for the Treatment of Chronic Hepatitis B

Fast Track designation has the potential to facilitate development and accelerate FDA review of imdusiran WARMINSTER, Pa., April 15, 2026 ...

Arbutus Biopharma Corporation

View Arbutus Biopharma Corporation ABUS stock quote prices, financial information, real-time forecasts, and company news from CNN.
Yahoo Finance

Here’s Why Arbutus (ABUS) Surged in Q3

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
FiercePharma

Moderna mounts defense in COVID-19 vaccine patent feud with Arbutus, Genevant

In its COVID-19 vaccine patent kerfuffle with Arbutus Biopharma and Roivant’s Genevant Sciences, mRNA hot shot Moderna aims to shield itself with its government contract, court documents filed Friday ...
FierceBiotech

Arbutus cans early-phase hep B program after 2 healthy people fall ill

Arbutus Biopharma is dumping one of its Roivant-backed programs after two healthy people in a phase 1 study developed acute hepatitis—the very disease the drug was supposed to treat. The company was ...
Forbes

Roivant Makes $116 Million Investment In Arbutus, Backing Battle With Moderna

Roivant Sciences and Moderna Therapeutics, two of the most highly-funded and controversial companies in the biotechnology world, are headed for a collision course over medical technology. On Monday, ...